Apogee Therapeutics had its Relative Strength (RS) Rating upgraded from 67 to 77 Friday — a welcome improvement, but still short of the 80 or better score you prefer to see.
This unique rating identifies technical performance by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research shows that the stocks that go on to make the biggest gains tend to have an RS Rating north of 80 in the early stages of their moves. See if Apogee Therapeutics can continue to rebound and hit that benchmark.
Can You Really Time The Stock Market?
While it's not currently an ideal time to invest, see if the stock manages to form a base and break out.
Apogee Therapeutics reported 0% earnings growth in the latest quarterly report, while sales growth came in at 0%.
The company holds the No. 224 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
